FierceBiotechOriginal article
{"a":[{"_":"MapLight shares sink on mixed phase 2 schizophrenia readout","$":{"href":"/biotech/maplight-shares-sink-mixed-ph-2-schizophrenia-readout","hreflang":"en"}}]}
Phase 2MixedNegative
AI Analysis
Summary
MapLight Therapeutics reported mixed Phase 2 results for its experimental schizophrenia treatment, causing the company's stock to plummet over 60%.
Clinical Trial Data
Phase
2
Outcome Details
Phase 2 trial of experimental schizophrenia treatment produced mixed results
Importance:7/10
Sentiment:
-0.85
Phase 2schizophreniamixed resultsstock decline
Read the original article
Published by FierceBiotech on July 27, 2026 10:35 AM